A recent cross-sectional study has evaluated the outcomes of currently used medical strategies for the treatment of LUTS in France, showing that treatment was unsatisfactory in about half of these patients. It is not clear whether this is due to the limited therapeutic effect of the available drugs or to their suboptimal use.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Garraway, W. M., Collins, G. N. & Lee R. J. High prevalence of benign prostatic hypertrophy in the community. Lancet 338, 469–471 (1991).
Rosen, R. et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 44, 637–649 (2003).
Fourcade, R. O. et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J. Urol. doi:10.1007/s00345-011-0756-2.
Oelke, M. et al. Guidelines on treatment of non neurogenic male LUTS. European Association of Urology 2011 guidelines [online], (2011).
Mc Vary, K. T. et al. Update on AUA guidelines on the management of benign prostatic hyperplasia. J. Urol. 185, 1793–1803 (2011).
Wei, J. T. et al. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J. Urol. 186, 971–976 (2011).
Apostolidis, A. et al. Gender and age differences in the perception of bother and health care seeking for lower urinary tract symptoms: results from the hospitalised and outpatients' profile and expectations study. Eur. Urol. 56, 937–947 (2009).
van Exel, N. J. et al. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur. Urol. 49, 92–102 (2006).
Fourcade, R. O., Theret, N., Taieb, C. & the BPH USAGE Study Group. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int. 101, 1111–1118 (2008).
Cornu, J. N., Cussenot, O., Haab, F. & Lukacs, B. A. Widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur. Urol. 58, 450–456 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
De Nunzio, C., Tubaro, A. Unmet needs in managing LUTS—a European perspective. Nat Rev Urol 9, 9–10 (2012). https://doi.org/10.1038/nrurol.2011.190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.190
This article is cited by
-
Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia
International Urology and Nephrology (2023)
-
Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
BMC Urology (2015)
